Nasdaq proposes stricter listing rules to enhance investor protection and market integrity, including higher minimum public float and capital raise requirements for Chinese firms.
Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.
Nasdaq proposes stricter listing rules to enhance investor protection and market integrity, including higher minimum public float and capital raise requirements for Chinese firms.
Sanofi's experimental eczema drug amlitelimab falls short of expectations, raising concerns about the company's ability to replace Dupixent's revenue after patent expiry.